“With no detectable divergences across our pillars, we adopt a proactive–cautious risk posture. The consensus view—rooted in the machine pillar’s emphasis on DNA methylation–driven dysregulation in atherosclerosis, myocardial infarction, and hypertension—is that epigenetic interventions (CRISPR/Cas9, RNA therapies, small-molecule epigenetic enzyme inhibitors) hold high promise for reducing global cardiovascular mortality. However, these approaches remain largely at preclinical or early clinical stages, warranting rigorous validation and safety monitoring before widespread deployment.”